周四，恒生指数飙升315点，收于23573点，涨幅1.4%，在美国法院裁定特朗普总统对美国贸易伙伴征收广泛关税超出其职权后，从前一天的下跌中恢复过来。尽管白宫对这一决定提出上诉，并可能将其升级到最高法院，但这一裁决让人们希望特朗普可能会缓解最高关税威胁。科技股领涨，因英伟达盈利强劲，上涨2.5%。消费股和金融股也上涨，瑞银将其2025年香港GDP增长预测从1%上调至2.2%，第一季度GDP强劲，美中关税暂停90天，IPO势头强劲，旅游业反弹。联邦公开市场委员会会议纪要显示，对与关税相关的通胀风险的担忧限制了进一步的涨幅。主要推动者包括老蒲金（7.6%）、美团（6.9%）、快手科技（4.7%）和Trip.com（3.3%）。随着中国计划改革药品定价，医药股大幅上涨，无锡生物制品上涨9.8%，信达生物制品上涨3.1%。

The Hang Seng surged 315 points or 1.4% to close at 23,573 on Thursday, recovering from the prior day’s drop after a U.S. court ruled that President Trump exceeded his authority by imposing broad tariffs on U.S. trade partners. Although the White House appealed the decision and could escalate it to the Supreme Court, the verdict raised hopes that Trump might ease the highest tariff threats. Tech stocks led gains, up 2.5% on strong earnings from Nvidia. Consumer and financial stocks also advanced, lifted by UBS raising its 2025 Hong Kong GDP growth forecast to 2.2% from 1%, amid robust Q1 GDP, a 90-day US-China tariff pause, strong IPO momentum, and a rebound in tourism. Further gains were capped by FOMC minutes showing concerns over inflation risks linked to tariffs. Key movers included Laopu Gold (7.6%), Meituan (6.9%), Kuaishou Tech (4.7%), and Trip.com (3.3%). Pharma stocks jumped as China plans to reform drug pricing, with Wuxi Biologics surging 9.8% and Innovent Biologics up 3.1%.